NSE IPO - Apply Online, Check Issue Date, Price, Lot Size & Allotment Status

Apply for NSE IPO:

Skip to main content
Sagimet Biosciences Inc. Series A Common Stock logo

Sagimet Biosciences Inc. Series A Common Stock Share Price

NASDAQ: SGMTHealthcare

$10.92

-0.24 (2.19%)

Live Sagimet Biosciences Inc. Series A Common Stock Share Price Chart

O H L

Sagimet Biosciences Inc. Series A Common Stock Performance Overview

Days Range
$10.80Low
$11.16High

Markets Today

Previous Close$11.17
Open$11.16
Volume160,495
Day's Range$10.80 - $11.16
52W Range$4.50 - $11.45
Market Cap$650.18 M

Historical Performance

1M Returns+5.58
3M Returns+67.22
6M Returns+129.84
1Y Returns+65.48
5Y ReturnsNA
10Y ReturnsNA

Sagimet Biosciences Inc. Series A Common Stock Fundamentals

Market Cap$650.18 M
Dividend yield0.00
PE Ratio0.00
PEG RatioN/A
Revenue$0.00
ROE TTM-0.38
EPS TTM$-1.28
Quarterly Earnings Growth YOYN/A
PB Ratio1.33
EBITDA$-56.89 M
Profit MarginN/A
Market Cap$650.18 M
Dividend yield0.00
PE Ratio0.00
PEG RatioN/A
Revenue$0.00
ROE TTM-0.38
EPS TTM$-1.28
Quarterly Earnings Growth YOYN/A
PB Ratio1.33
EBITDA$-56.89 M
Profit MarginN/A

Sagimet Biosciences Inc. Series A Common Stock Profit & Loss

Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Total Revenue +$0$0$0$0$0$0
Gross Profit +$0$0$0$0$0$0
Operating Income -$19.86 M-$11.93 M-$14.33 M-$10.77 M-$11.71 M-$15.82 M
EBITDA -$19.86 M-$11.93 M-$14.33 M-$10.77 M-$11.71 M-$15.82 M
Interest Expense $0$0$0$0$0$0
Depreciation $0$0$0$0$0$0
Income Before Tax -$18.18 M-$10.39 M-$12.91 M-$9.57 M-$10.65 M-$13.95 M
Income Tax Expense $0$0$0$0$0$0
Net Income +-$18.18 M-$10.39 M-$12.91 M-$9.57 M-$10.65 M-$13.95 M
Net Profit Margin ------

Sagimet Biosciences Inc. Series A Common Stock Financials Balance Sheet In USD

Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Share Capital $3.00 K$3.00 K$3.00 K$3.00 K$3.00 K$6.00 K
Reserve & Surplus -$313.37 M-$323.80 M-$336.66 M-$346.23 M-$356.99 M-$371.03 M
Non-Current Liabilities $0$0$0$0$0$1.86 M
Current Liabilities $7.18 M$7.25 M$9.15 M$5.10 M$5.30 M$5.42 M
Total Liabilities $7.18 M$7.25 M$9.15 M$5.10 M$5.30 M$7.28 M
Fixed Assets $0$0$0$0$0$0
Current Assets $146.07 M$127.20 M$119.48 M$116.40 M$107.72 M$243.99 M
Total Assets $146.17 M$137.41 M$128.40 M$116.48 M$107.75 M$263.43 M

Sagimet Biosciences Inc. Series A Common Stock Cash Flow

Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Net Income -$18.18 M-$10.39 M-$12.91 M-$9.57 M-$10.65 M-$13.95 M
Operating Cash Flow -$14.54 M-$9.10 M-$10.18 M-$11.83 M-$8.61 M-$11.10 M
Investing Cash Flow $3.41 M-$13.29 M$75.00 K$14.36 M$10.22 M-$24.02 M
Financing Cash Flow $0$1.00 K$274.00 K$0$0$164.39 M
Change in Cash -$11.12 M-$22.39 M-$9.83 M$2.52 M$1.60 M$129.27 M

Sagimet Biosciences Inc. Series A Common Stock Return Calculator

The Sagimet Biosciences Inc. Series A Common Stock stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Returns Estimator

Based on past performance of this fund

ENTER AMOUNT
$10,000
Select Duration
5Yrs
1 Yr5 Yrs
If you had invested $10,000 5 years ago, what would its value be today?$10,000
Invested Amount$10,000
Est. Returns$0
Invest in USA Stock Today

About Sagimet Biosciences Inc. Series A Common Stock

Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.

FAQs

Sagimet Biosciences Inc. Series A Common Stock (SGMT) share price as of September 18, 2026 is $10.92. If you are investing from India, you can always check the valuation in the INR before investing.
Yes, Indian Investors can invest in the Sagimet Biosciences Inc. Series A Common Stock (SGMT) Share by opening an international trading account with Angel One.
Purchasing Sagimet Biosciences Inc. Series A Common Stock (SGMT) share from India can be done by: Directly: By opening an international trading account with Angel One. The process would include KYC verification. The account activation takes a few minutes to a few hours, after which you can start buying Sagimet Biosciences Inc. Series A Common Stock (SGMT) by making deposits in US dollars. Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.
Yes, you can purchase fractional shares of Sagimet Biosciences Inc. Series A Common Stock (SGMT) or any other US company shares in Angel One for any dollar amount.
The market capitalization of Sagimet Biosciences Inc. Series A Common Stock on September 18, 2026, is $650.18 M.
Sagimet Biosciences Inc. Series A Common Stock operates in the Healthcare sector, specifically in the Healthcare industry.
In order to invest in Sagimet Biosciences Inc. Series A Common Stock (SGMT) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.). From start to end, the process is digital and can be seamless.

Diversify Your Portfolio with US Stocks

Invest in Wall Street Giants from India

+91
Top US Stocks

VIEW ALL

Open Free Demat Account!

Join our 3.8 Cr+ happy customers
+91